‘TRexit’ is a national initiative that could see a move away from transrectal (TRUS) biopsy, requiring an anaesthetic, to performing transperineal biopsy under local anaesthetic.
‘TRexit’ is a national initiative that could see a move away from transrectal (TRUS) biopsy, requiring an anaesthetic, to performing transperineal biopsy under local anaesthetic. Technology developments in this field have the potential to lower costs, shorten waiting lists and improve patient safety.
Statistics1 released by NHS England have shown that hundreds of thousands of patients across the country are now waiting more than a year to receive hospital treatment – a direct result of the COVID-19 pandemic. Many of these include cancer patients. Analysis of NHS England data2 shows that 1.85 million urgent cancer referrals were made by GPs between March last year and January this year – a 16% drop on the 2.2 million in the same period the year before.
This backlog is concerning to many healthcare professionals, with a recent survey3 finding that 70% of respondents are concerned about the backlog of procedures at their hospital Trust, and 68% believing that delays to surgical procedures are having a negative impact on patient outcomes.
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.